Progestational Agents

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	DS – Maximum Days' Supply Allowed	PU – Prior Use of Other Medication is Required
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	DT – Duration of Therapy Limit	QL – Quantity Limit
BY – Diagnosis Codes Bypass Some Requirements	DX – Diagnosis Code Requirement	RX – Specific Prescription Requirement
CL – Additional Clinical Information is Required	ER – Early Refill	TD – Therapeutic Duplication
CU – Concurrent Use with Other Medication is Restricted	MD – Maximum Dose Limit	YQ – Yearly Quantity Limit
DD – Drug-Drug Interaction	MME – Maximum Morphine Milligram Equivalent is Restricted	

Progestational Agents

POS Edits

DX – Diagnosis codes can be found at <u>THIS LINK</u>.

- Pharmacy claims for these agents must be submitted with a valid diagnosis code for recipients who are younger than 18 years of age.
- Pharmacy claims for progesterone, micronized, vaginal (Crinone®) require an appropriate diagnosis code for any age.
- Pharmacy claims for injectable progesterone must be submitted with a valid diagnosis code for recipients of any age.

Revision / Date	Implementation Date
Created POS Document	February 2020
Updated age for BH in POS Abbreviations chart / November 2020	January 2021
Removed hydroxyprogesterone caproate for pre-term labor / April 2023	April 2023
Formatting changes / August 2023	October 2023
Added diagnosis code requirement for recipients younger than 18 years of age / August 2023	January 2024

Progestational Agents

Added diagnosis code requirement for recipients of any age for injectable progesterone / May 2024	October 2024